Kyushu University Academic Staff Educational and Research Activities Database
Researcher information (To researchers) Need Help? How to update
Makoto Endo Last modified date:2021.08.14



Other Organization


E-Mail *Since the e-mail address is not displayed in Internet Explorer, please use another web browser:Google Chrome, safari.
Homepage
https://kyushu-u.pure.elsevier.com/en/persons/makoto-endo
 Reseacher Profiling Tool Kyushu University Pure
http://www.ortho.med.kyushu-u.ac.jp
Dept. of orthopaedic surgery, Kyushu Univ. .
Phone
092-642-5488
Fax
092-642-5507
Academic Degree
M.D., Ph. D.
Country of degree conferring institution (Overseas)
No
Field of Specialization
Bone and soft tissue tumor, Sarcoma
ORCID(Open Researcher and Contributor ID)
0000-0002-7956-2190
Total Priod of education and research career in the foreign country
01years00months
Outline Activities
#1. Clinical activities: diagnosis and treatment of patients with bone and soft tissue tumors including metastatic tumors, #2. Research: clinical, clinicopathological and biological research on bone and soft tissue sarcomas
Research
Research Interests
  • Clinicopathological and molecular biological research on bone and soft tissue tumors
    keyword : bone and soft tissue tumor, sarcoma
    2013.04~2028.03.
Current and Past Project
  • JCOG bone and soft tissue tumor group
Academic Activities
Papers
1. Makoto Endo, Hidetaka Yamamoto, Nokitaka Setsu, Kenichi Kohashi, Yusuke Takahashi, Takeaki Ishii, Kei-ichiro Iida, Yoshihiro Matsumoto, Michiyuki Hakozaki, Mikiko Aoki, Hiroshi Iwasaki, Yoh Dobashi, Kenichi Nishiyama, Yukihide Iwamoto, Yoshinao Oda, Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors, Clinical Cancer Research, 10.1158/1078-0432.CCR-12-1067, 19, 2, 450-461, 2013.01, PURPOSE:
Malignant peripheral nerve sheath tumor (MPNST) is a rare soft tissue sarcoma with poor prognosis. MPNSTs occur frequently in patients with neurofibromatosis type 1 (NF1), in which NF1 gene deficiency leads to Ras hyperactivation. Ras activation causes the subsequent activation of the AKT/mTOR and Raf/MEK/ERK pathways and regulates cellular functions. However, the activation profiles of the AKT/mTOR and MAPK pathways in MPNSTs are poorly understood. The purposes of this study are to examine the correlation between the activation of these pathways and clinicopathologic or prognostic factors and to identify candidate target molecules in MPNST. Moreover, we assessed the antitumor effects of the inhibitor of candidate target.
EXPERIMENTAL DESIGN:
Immunohistochemistry was conducted to evaluate the activation profiles of AKT/mTOR and MAPK pathways using 135 tumor specimens. Immunohistochemical expressions were confirmed by Western blotting. Then, an in vitro study was conducted to examine the antitumor effect of the mTOR inhibitor on MPNST cell lines.
RESULTS:
Phosphorylated-AKT (p-AKT), p-mTOR, p-S6RP, p-p70S6K, p-4E-BP1, p-MEK1/2, and p-ERK1/2 expressions were positive in 58.2%, 47.3%, 53.8%, 57.1%, 62.6%, 93.4%, and 81.3% of primary MPNSTs, respectively. Positivity for each factor showed no difference between NF1-related and sporadic MPNSTs. Univariate prognostic analysis revealed that p-AKT, p-mTOR, and p-S6RP expressions were associated with poor prognosis. Furthermore, activation of each p-mTOR and p-S6RP was an independent poor prognostic factor by multivariate analysis. mTOR inhibition by Everolimus showed antitumor activity on MPNST cell lines in vitro.
CONCLUSION:
mTOR inhibition is a potential treatment option for both NF1-related and sporadic MPNSTs..
2. Makoto Endo, Chikashi Kobayashi, Nokitaka Setsu, Yusuke Takahashi, Kenichi Kohashi, Hidetaka Yamamoto, Sadafumi Tamiya, Shuichi Matsuda, Yukihide Iwamoto, Masazumi Tsuneyoshi, Yoshinao Oda, Prognostic Significance of p14(ARF), p15(INK4b), and p16(INK4a) Inactivation in Malignant Peripheral Nerve Sheath Tumors, Clinical Cancer Research, 10.1158/1078-0432.CCR-10-2393, 17, 11, 3771-3782, 2011.06, PURPOSE:
p14(ARF), p15(INK4b), and p16(INK4a) are tumor suppressor genes that are located closely at 9p21 and are often coinactivated by genetic or epigenetic alterations. Malignant peripheral nerve sheath tumor (MPNST) is a rare sarcoma with poor prognosis. However, the prognostic implications of inactivation of p14(ARF), p15(INK4b), and p16(INK4a) in MPNSTs have not been adequately investigated. Here we carried out a genetic, epigenetic, and expression analysis of p14(ARF), p15(INK4b), and p16(INK4a), and clarified the prognostic significance of their inactivation in MPNSTs.
EXPERIMENTAL DESIGN:
p14(ARF), p15(INK4b), and p16(INK4a) protein expressions were assessed by immunohistochemistry in 129 formalin-fixed samples of MPNST including 85 primary tumors. Thirty-nine samples, for which frozen material was available, were also investigated by Western blotting and quantitative reverse transcription PCR (RT-PCR) to detect p14(ARF), p15(INK4b), and p16(INK4a) protein and mRNA expression, and by multiplex real-time PCR, PCR single strand conformation polymorphism and methylation-specific PCR to detect p14(ARF), p15(INK4b), and p16(INK4a) gene alterations.
RESULTS:
Immunohistochemically decreased expressions of p14(ARF), p15(INK4b), and p16(INK4a) were observed in 48%, 54%, and 49% of primary MPNSTs, respectively, and were significantly correlated with their concordant mRNA levels. As for gene alterations, homozygous deletion of CDKN2A was detected in one third of the cases. Inactivation of p14(ARF) and p16(INK4a) was associated with poor prognosis by both univariate and multivariate analyses. Furthermore, cases with inactivation of all p14(ARF), p15(INK4b), and p16(INK4a) genes showed the worst prognosis in a combined prognostic assessment.
CONCLUSION:
A comprehensive analysis of p14(ARF), p15(INK4b), and p16(INK4a) inactivation status provides useful prognostic information in MPNSTs..
Presentations
1. Quincy S-C Chu, Thierry Alcindor, Abha Gupta, Makoto Endo, Angela Goytain, Hao Xu, Shaliendra Verma, Richard Tozer, Meg Knowling, Vivien Bramwell, Jean Powers, Lesley Seymour, Torsten Nielsen, A Phase II Study of SB939, A Novel Pan-Histone Deacetylase Inhibitor, in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas - NCIC-CTG IND 200., The 18th Annual Meeting of Connective Tissue Oncology Society, 2013.10.
2. Makoto Endo, Davis R. Ingram, Simin Lim, Dina C. Lev, Marieke A. de Graaff, Judith V.M.G. Bovée, Alexander J. Lazar, Torsten O. Nielsen, NY-ESO-1 Expression in Myxoid Liposarcoma and Other Mesenchymal Tumors: An International Validation Study, The 18th Annual Meeting of Connective Tissue Oncology Society, 2013.10.
Membership in Academic Society
  • Japanese Association of Sarcoma Treatment and Research
  • Japanese Association of Rehabilitation Medicine
  • European Society for Medical Oncology
  • Connective Tissue Oncology Society
  • Japan Society of Clinical Oncology
  • Japanese Orthopaedic Association
  • Japanese Society of Medical Oncology
  • Japanese Cancer Asssociation
  • West-Japanese Society of Orthopedics and Traumatology
Awards
  • Development of novel immunotherapy for bone and soft tissue tumors
  • Development of novel immunotherapy for malignant bone and soft tissue tumors
  • Exploratory research for prognostic factors and novel therapeutic targets in bone and soft tissue tumors
Educational
Educational Activities
#1. Diagnosis and treatment of patients with bone and soft tissue tumors, #2. Translational study and molecular biology of bone and soft tissue tumors